Foot Ulcer, Diabetic
Conditions
Brief summary
This is a 10-week, randomized, controlled study to evaluate the efficacy and safety of the APT001 plasma and nitric oxide treatment in subjects with a diabetic foot ulcer.
Detailed description
Approximately 80 subjects will be randomized by computer to receive equally either sham therapy or plasma / nitric oxide treatments topically. The nitric oxide / plasma treatment will be delivered from 11.5 to 15 centimeters from the wound surface for 10 seconds per cm2 of wound size. Subjects will be evaluated for efficacy and safety on a regular basis with clinical observations. The wounds of both groups will be treated with sharp debridement as determined by the site Investigator. A collagen dressing, a non-adherent dressing, and an absorptive dressing will be applied to the wound after either the study therapy or the sham therapy. For an initial safety evaluation in patients with DFU, the first ten patients randomized will be limited to wound size of 7 cm2 or less and their wounds will be assessed 2-4 days after each treatment session. Following completion of the final assessment in these 10 patients, data will be submitted to FDA for review and approval before opening the enrolment for the remaining patients.
Interventions
DEVICEAPT001
APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
DEVICESHAM
Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
Sponsors
Origin Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 19 to 80 years of age * Type 1 or 2 diabetes with hemoglobin A1c less than 12% * ABI ≥ 0.7, palpable pulses and/or biphasic waveform study with Doppler * Wound size ≥ 1cm2 and ≤ 30cm2 (the first 10 patients enrolled will be limited to a wound size of 7 cm2 or less)
Exclusion criteria
* Have a significant concomitant illness that would adversely affect participation in the study or affect the healing of the wound * Have a severe infection in the ulcer including the presence of an abscess, cellulitis extending \> 2 cm beyond the ulcer margin, or osteomyelitis * Have involvement of deeper tissues including bone or tendon * Be currently receiving steroid medications, chemotherapy, or other medications that might affect healing of the wound * Have received topical or systemic antimicrobial therapy within 48 hours of screening * Have a malignancy other than skin cancer currently being treated * Have substance abuse issues within the 6 months prior to screening * Is a woman who is pregnant or breast feeding * Has been treated with another investigational product within 30 days of screening * Has been treated with tissue engineered skin or a biological therapy within 30 days of screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent change in total wound size | Baseline to end of Week 10 | Change in total wound size using dimensional measurements of the wound and using the Aranz SilhouetteStar + SilhouetteConnect wound assessment device from Baseline to Week 10. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in bacterial load | Baseline to end of Week 5 | Clearance of wound infection based on clinical observation and wound biopsy cultures. |
| Wound pain | Baseline to end of Week 10 | Wound pain measured by a standard wound pain scale completed at each visit prior to treatment or any study procedures. |
Countries
United States
Outcome results
None listed